← Back to Screener
LB Pharmaceuticals Inc Common Stock (LBRX)
Price$28.03
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)61.21%
Price vs S&P 500 (4W)-15.98%
VGM Score68.00
Market Capitalization$802.09M
All Metrics
Book Value / Share (Quarterly)$13.21
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.04
Price vs S&P 500 (YTD)14.72%
EPS (TTM)$-1.72
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-1.72
EPS (Annual)$-1.00
ROI (Annual)-8.37%
Cash / Share (Quarterly)$12.75
ROA (Last FY)-8.05%
EBITD / Share (TTM)$-2.06
Cash Flow / Share (Annual)$-1.39
P/B Ratio2.12x
P/B Ratio (Quarterly)1.87x
Net Income / Employee (Annual)$-933,500
ROA (TTM)-16.92%
EPS Incl Extra (Annual)$-1.00
Current Ratio (Annual)41.44x
Quick Ratio (Quarterly)33.53x
3-Month Avg Trading Volume0.23M
Revenue / Employee (TTM)$0
52-Week High$33.47
EPS Excl Extra (Annual)$-1.00
26-Week Price Return77.14%
Quick Ratio (Annual)39.67x
13-Week Price Return15.44%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)35.68x
Enterprise Value$481.41M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$11.67
3-Month Return Std Dev54.81%
Net Income / Employee (TTM)$-1,639,200
ROE (Last FY)-8.37%
EPS Basic Excl Extra (Annual)$-1.00
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.72
ROI (TTM)-17.69%
Revenue / Share (Annual)$0.00
Year-to-Date Return25.65%
5-Day Price Return-0.53%
EPS Normalized (Annual)$-1.00
Month-to-Date Return-11.79%
EBITD / Share (Annual)$-1.19
EPS Basic Excl Extra (TTM)$-1.72
P/B Ratio (Annual)1.87x
Book Value / Share (Annual)$11.91
Price vs S&P 500 (13W)5.69%
Beta1.52x
Revenue / Share (TTM)$0.00
ROE (TTM)-17.69%
52-Week Low$13.36
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.67est. -0.76
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.30
4.30
4.30
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | — | — | B | $28.03 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders including schizophrenia and bipolar depression. Its lead candidate, LB-102, is a novel benzamide antipsychotic with the potential to be the first of its kind approved in the United States, based on amisulpride, an antipsychotic already approved in over 50 countries.